Inhibikase Therapeutics Inc reports results for the quarter ended in March - Earnings Summary

Inhibikase Therapeutics

17/05/2022 24:16

* Inhibikase Therapeutics Inc  IKT.OQ  reported a quarterly
adjusted loss of 18 cents​​ per share for the quarter ended in
March. The lone analyst forecast for the quarter was for a loss
of 17 cents per share.
    * Revenue fell 96.7% to $46.03 thousand from a year ago; 
analysts
expected $300.00 thousand. 
    * Inhibikase Therapeutics Inc's reported EPS for the quarter
was a
loss of 18 cents​.
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Inhibikase Therapeutics Inc shares had fallen by 54.7%
this
quarter and lost 54.4% so far this year.
    * The company reported a quarterly loss of $4.64 million.
    * Wall Street's median 12-month price target for Inhibikase
Therapeutics Inc is $6.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 1 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated May 16 at 11:16 p.m.  ​All
figures in US dollars unless otherwise stated